Tecelra Receives Full FDA Approval with Expanded Pediatric Indication in Synovial Sarcoma
On June 22, 2026, the US Food and Drug Administration (FDA) granted full approval to US WorldMeds’ Tecelra® (afamitresgene autoleucel), converting its prior accelerated approval and expanding its indication to include patients aged 12 years and older who have unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the melanoma-associated antigen A4 (MAGE-A4 antigen). This is an autologous engineered T-cell receptor (TCR) therapy that uses a patient’s genetically modified T cells to recognize and target MAGE-A4–expressing tumor cells. The treatment is administered as a one-time intravenous (IV) infusion following lymphodepleting chemotherapy. Approval was based on an open-label, single-arm study of 137 patients demonstrating an overall response rate (ORR) of 43.8%, including a complete response rate of 3.6%, with a median duration of response of 5.3 months. Tecelra represents the first approved engineered T-cell therapy for a solid tumor. Safety considerations include risks of cytokine release syndrome (CRS), neurologic toxicities, cytopenias, and infections. The prescribing information may be found here.
Ibrance Gains New Indication in HR+/HER2+ Metastatic Breast Cancer
On June 24, 2026, the FDA approved a new indication for Pfizer’s Ibrance® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer following induction therapy. Initially approved for HR‑positive, HER2‑negative metastatic breast cancer in combination with endocrine therapy, Ibrance is a kinase inhibitor that blocks cyclin-dependent kinases (CDK4 and CDK6) to limit cancer cell growth. This new indication adds a CDK4/6 inhibitor to established anti‑HER2 and endocrine backbone therapy to delay disease progression. Approval was based on a statistically significant improvement in progression‑free survival (PFS) with the palbociclib-containing regimen, including an approximately 24% reduction in the risk of disease progression or death when compared with standard therapy alone. It is taken on 28-day cycles, with a recommended dose of one 125mg capsule taken daily, along with food, on days one through 21, followed by seven days without Ibrance. Key safety considerations include neutropenia, interstitial lung disease/pneumonitis, and embryo‑fetal toxicity. For its full prescribing information, please look here.
FDA Expands Tryngolza to Severe Hypertriglyceridemia Population with Pancreatitis Risk Data
On June 24, 2026, the FDA approved Ionis Pharmaceuticals’ Tryngolza® (olezarsen) subcutaneous (SC) autoinjector as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, defined as 500 mg/dL or greater. More than 3 million Americans are estimated to have this condition. The antisense oligonucleotide, initially approved in 2024 for familial chylomicronemia syndrome, targets apolipoprotein C‑III to enhance triglyceride clearance. Approval was based on rapid and sustained triglyceride reductions of up to 72% versus placebo at six months, maintained through 12 months, along with reductions in acute pancreatitis events of up to 91%. The recommended dose is 50mg SC once monthly, with self-administration in the abdomen or thigh. This approval is notable as it expands treatment from a rare genetic population to a broader severe hypertriglyceridemia population while representing the first therapy in this setting to demonstrate a reduction in acute pancreatitis risk, an outcome not previously established in trials of triglyceride-lowering agents. Here is the updated prescribing information.
Trodelvy Expanded into First-Line TNBC with Two New Indications
On June 24, 2026, the FDA approved Gilead Sciences’ Trodelvy® (sacituzumab govitecan-hziy) for two expanded indications for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). First, as monotherapy in patients ineligible for Programmed Death-(PD)-1/Programmed Death-Ligand (PD-L) 1 inhibitors and second, in combination with Keytruda® (pembrolizumab – Merck) and Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph – Merck) for patients with PD-L1–positive tumors. Trodelvy is a Trop-2–directed antibody-drug conjugate delivered via IV infusion, initially approved in 2020 as a third-line treatment. Approval was based on the phase III ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, which demonstrated improved progression-free survival (PFS) compared with chemotherapy-based regimens, with median PFS of 9.7 months versus 6.9 months in the monotherapy study and 11.2 months versus 7.8 months in the combination study, along with higher response rates and more durable disease control with the combination. The recommended dose is 10mg/kg IV on days one and eight of 21-day cycles until disease progression or unacceptable toxicity. Key safety considerations include boxed warnings for severe neutropenia and diarrhea, along with risks of infusion-related reactions and embryo-fetal toxicity. Here is the updated prescribing information.
BESREMi Pen Approval and Launch
The FDA approved PharmaEssentia USA’s BESREMi Pen™ (ropeginterferon alfa‑2b‑njft) prefilled pen on June 26, 2026, for the treatment of adults with polycythemia vera (PV). This approval builds on the prior approval of BESREMi SC injection in a pre-filled syringe and introduces a novel pen delivery system designed to simplify self-administration. PV is a chronic myeloproliferative neoplasm characterized by excessive red blood cell production. The recommended administration remains SC injections once every two weeks at 100mcg, which can be increased in 50mcg increments up to a maximum of 500mcg/dose depending on the patient’s response to treatment. If blood components have stabilized after one year of therapy, treatments may be changed to once every four weeks. The BESREMi Pen is expected to become commercially available in the US in the coming weeks.
First Generic Rifapentine Approved
The FDA approved the first generic version of Sanofi’s Priftin® (rifapentine) tablets on June 23, 2026, for the treatment of active pulmonary tuberculosis caused by Mycobacterium tuberculosis in combination with other susceptible antituberculosis drugs in patients aged 12 years and older, and for latent tuberculosis infection in combination with isoniazid in patients aged two years and older at high risk of progression. Macleods Pharmaceuticals’ generic version is now approved, though no launch or cost info is available. Annual US sales for 2025 are estimated to be under $10 million.
Generic Bosulif Tablets Launch
Dr. Reddy’s Laboratories announced the launch of bosutinib tablets 400mg with 180 days of generic drug exclusivity on June 15, 2026. Alembic launched its generic 100mg and 500mg bosutinib tablets on or about June 11, 2026. Sun also has generic 100mg, 400 mg, and 500mg tablets in development, with the 400mg expected to launch after the exclusivity period, and the launch of the 100mg and 500mg tablets unclear due to a settlement agreement. The reference product, Bosulif® (bosutinib – Pfizer) is a tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML). Bosulif generated approximately $755 million in US sales in 2025.
Generic Edarbi Launched
On June 17, 2026, Lupin Limited announced the launch of azilsartan medoxomil tablets, the generic equivalent of Edarbi® (Takeda) in 40mg and 80mg strengths for the treatment of hypertension in adults to lower blood pressure. The reference product recorded approximately $53.5 million in US annual sales for the 12 months ending April 2026. Multiple entrants are expected after the exclusivity period ends in mid-December.